FDA-cleared profile

Radiation Planning Assistant (RPA)

University of Texas, MD Anderson Cancer Center · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Radiation Planning Assistant creates initial CT-based contours and photon external-beam treatment plans for head-and-neck, cervical, breast, and whole-brain radiotherapy; every result must be imported into the user's treatment-planning system for review, editing, and final dose calculation.

Clinical role
Automated contouring, plan generation, dose optimization, and quality-control support before independent TPS review and calculation.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyRadiotherapy Planning Imaging · Multi-region
  • Workflow roleAutomated contouring, plan generation, dose optimization, and quality-control support before independent TPS review and calculation.
  • Required inputRadiotherapy planning CT images and required clinical planning inputs.
  • Output and human actionInitial contours and external-beam photon plans for import into the user's treatment-planning system.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Radiation Planning Assistant creates initial CT-based contours and photon external-beam treatment plans for head-and-neck, cervical, breast, and whole-brain radiotherapy; every result must be imported into the user's treatment-planning system for review, editing, and final dose calculation.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Automated contouring, plan generation, dose optimization, and quality-control support before independent TPS review and calculation.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Radiotherapy planning CT images and required clinical planning inputs.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Initial contours and external-beam photon plans for import into the user's treatment-planning system.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Radiation-oncology departments, including resource-constrained clinics able to support the required CT and treatment-planning workflow.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
K222728 describes large training sets and multicenter performance testing at five sites using Philips, Siemens, and GE CT data. Site-specific tests covered cervical, chest-wall, head-and-neck, and whole-brain planning, with explicit contour, dosimetry, isocenter, and plan-review criteria plus documented cervical VMAT exceptions requiring careful local acceptance.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K222728 describes large training sets and multicenter performance testing at five sites using Philips, Siemens, and GE CT data. Site-specific tests covered cervical, chest-wall, head-and-neck, and whole-brain planning, with explicit contour, dosimetry, isocenter, and plan-review criteria plus documented cervical VMAT exceptions requiring careful local acceptance.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Clinical evaluation sites

5 sites

  • EndpointMulticenter planning evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Head-and-neck evaluation patients

86 patients

  • EndpointRPA head-and-neck plan evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix VMAT evaluation patients

50 patients

  • EndpointRPA cervical VMAT plan evaluation
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix surface Dice criterion

0.8 DSC

  • EndpointBody contours within 2 mm for 95% of CT scans
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

Cervix isocenter criterion

3 mm

  • EndpointAgreement in all orthogonal directions for 95% of cases
  • PopulationRadiation Planning Assistant (RPA)
  • Tested versionRadiation Planning Assistant release cleared in K222728

K222728 FDA performance package for Radiation Planning Assistant (RPA)

  • DesignManufacturer multicenter external evaluation of automated contours and treatment plans against clinical contours, plans, and dosimetric criteria
  • PopulationCervical, post-mastectomy chest-wall, head-and-neck, and whole-brain radiotherapy cases from five clinical sites
  • Scopeexact submission
  • Tested versionRadiation Planning Assistant release cleared in K222728
  • Sites5
  • IndependenceSponsor or vendor study

K222728

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K222728 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Radiotherapy planning CT images and required clinical planning inputs.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K222728: Radiation Planning Assistant (RPA)

  2. Routing

    Source context, not route validation: Uses some Eclipse 15.6 functions and exports contours and plans to the user's TPS; validate DICOM transfer, structure naming, beam model, machine configuration, dose recalculation, plan integrity, and failure recovery.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K222728: Radiation Planning Assistant (RPA) · Radiation Planning Assistant

  3. AI processing

    Source context, not route validation: Web-based planning software with site-specific integration to CT, network, and treatment-planning infrastructure; current no-cost access goals are product-family context, not a guaranteed commercial term.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K222728: Radiation Planning Assistant (RPA) · Radiation Planning Assistant

  4. Returned objects

    Source context, not route validation: Initial contours and external-beam photon plans for import into the user's treatment-planning system.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K222728: Radiation Planning Assistant (RPA)

  5. Viewer/worklist/report

    Unresolved route: Initial contours and external-beam photon plans for import into the user's treatment-planning system.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K222728: Radiation Planning Assistant (RPA)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Web-based planning software with site-specific integration to CT, network, and treatment-planning infrastructure; current no-cost access goals are product-family context, not a guaranteed commercial term.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Uses some Eclipse 15.6 functions and exports contours and plans to the user's TPS; validate DICOM transfer, structure naming, beam model, machine configuration, dose recalculation, plan integrity, and failure recovery.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified radiation oncologists, medical physicists, dosimetrists, and trained radiation-therapy planning staff. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K222728 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Uses some Eclipse 15.6 functions and exports contours and plans to the user's TPS; validate DICOM transfer, structure naming, beam model, machine configuration, dose recalculation, plan integrity, and failure recovery.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: RPA is not a primary treatment-planning system. Every contour and plan must be imported into the user's TPS for review, editing, and final dose calculation; unsupported disease sites, techniques, machines, or local protocols must not be inferred.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K222728
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-05-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
9Source classes checked
20Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 20 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 2 history items

Source ledger

  1. FDA K222728: Radiation Planning Assistant (RPA)

    U.S. Food and Drug Administration - Published 2023-05-17 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Radiation Planning Assistant

    The University of Texas MD Anderson Cancer Center - Accessed 2026-09-03

    Scope: productFamily, workflowRole, deployment, implementationCapabilities, currentCommercialContext

Research history

  1. K222728 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K241490

Contour+ (MVision AI Segmentation)

MVision AI Oy

Authorized purpose: Contour+ generates initial CT and MR anatomical contours across head and neck, brain, breast, thoracoabdominal, and pelvic radiation-treatment planning workflows for qualified review and approval.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2024-10-18
FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history